好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Symptom Severity and Quality of Life in Sarcoidosis-associated Small Fiber Neuropathy
Autoimmune Neurology
P5 - Poster Session 5 (11:45 AM-12:45 PM)
1-005
To explore differences in symptoms, quality of life, and disease severity in patients with sarcoidosis with and without Small Fiber Neuropathy (SFN).   
SFN occurs frequently in patients with systemic sarcoidosis and can affect quality of life. It is uncertain if this is due to inflammatory disease activity.  
Cross-sectional study including subjects with biopsy-proven systemic sarcoidosis with and without SFN and non-sarcoidosis SFN. Questionnaires were used to assess symptoms and quality of life: Pain Effects Scale (PES), King’s Sarcoidosis Questionnaire (KSQ), Modified Fatigue Impact Scale (MFIS), SFN Screening List (SFNSL), Rasch-Transformed SFN-Symptoms Inventory Questionnaire (RT-SFN-SIQ). Sarcoidosis organ involvement and disease activity markers were recorded.  
16 subjects had systemic sarcoidosis alone (SS), 8 had sarcoidosis-associated SFN (S-SFN), and 6 had non-sarcoidosis SFN. Compared to the SS group, the S-SFN group had more severe pain (PES 20.5 vs. 6.0, p<0.05), fatigue (MFIS 15.0 vs. 7.0, p<0.05), dysautonomia symptoms per RT-SFN-SIQ (13.9 vs. 5.9, p<0.05) and SFNSL (33.9 vs. 9.3, p<0.05), and worse sarcoidosis-related disability per KSQ score (79.3 vs. 59.3, p=0.08). No significant differences were found in these scores between S-SFN and non-sarcoidosis SFN. None of the S-SFN cases had diabetes, alcohol use disorder, or vitamin deficiencies. There was no age or sex difference between SS and S-SFN. Patients with S-SFN were older than patients with non-sarcoidosis SFN (59.0 vs. 48.3 y/o, p=0.13). Extrapulmonary involvement was common in both the SS (n=15/16) and the S-SFN group (n=6/8). The SS group had higher levels of Vit-D-1,25-OH D (59.7 vs. 43.3 pg/ml, p<0.05) and serum sIL2R (1719 vs.1477 pg/ml,p=0.29) than the S-SFN group.   
Patients with sarcoidosis who develop SFN have worse pain, fatigue, dysautonomia, and quality of life than patients without SFN. Proposed markers of sarcoidosis disease activity sIL2-R and Vit-D-1,25-OH may not be relevant in the assessment of S-SFN, though larger studies are needed.  
Authors/Disclosures
Sofia Ramirez Guerrero, MD
PRESENTER 		Dr. Ramirez Guerrero has nothing to disclose.
María Paula Aguilera Peña, MD María Paula Aguilera Peña, MD has nothing to disclose.
Elizabeth Frame, MD The institution of Dr. Frame has received research support from HealthNetwork Foundation. Dr. Frame has received personal compensation in the range of $500-$4,999 for serving as a Steering Committee member with Foundation for Sarcoidosis Research.
Bobak Akhavan, MD Dr. Akhavan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ANI Pharmaceuticals .
Evan Kransdorf, MD Dr. Kransdorf has nothing to disclose.
Paula Barreras, MD (Cedars-Sinai Medical Center) Dr. Barreras has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Barreras has received research support from Foundation for Sarcoidosis Research. The institution of Dr. Barreras has received research support from 好色先生.